Search
# Popular search #
中文站
# Popular search #
Ranked on the 2023 China Pharmaceutical Industry Comprehensive Competitiveness Index
Listed on the 2023 Top 100 Beijing Private Enterprises in "Technological Innovation" and "Social Responsibility"
Ranked on 2023 China Pharmaceutical R&D Strength Ranking Series Lists
Awarded "Forbes China Best Innovative Practice Employer of the Year 2023"
Gan & Lee Pharmaceuticals obtained Customs AEO (Authorized Economic Operator) Certification
Ranked among Top 20 Chinese Biopharmaceutical Enterprises (including Blood Products, Vaccines, Insulin, etc.) 2023
Awarded Pharmaceutical Industry Excellence Award (2024)
Honored as "Overseas Expansion Enterprise of the Year with the Most Investment Value"
Re-certified as a National High-Tech Enterprise
Ranked 40th on the 2024 Beijing Top 100 High-Precision and Advanced Enterprises list
Ranked 48th on the 2024 Beijing Top 100 Manufacturing Enterprises list
Designated as a Beijing Smart Factory (First Batch, 2024)
Clinical Progress of Innovative Insulin GZR Series recognized among "Tongzhou Innovation Partnership Program – Annual Top 10 Achievements"
Awarded the Pharmaceutical & Biotech Industry Track Champion Award (2022)
Ranked on the "2023 China Pharmaceutical Industry Comprehensive Competitiveness Index"
Ranked among the "Top 100 Chinese Pharmaceutical Companies in R&D Comprehensive Strength (2023)"
Ranked among the "Top 50 Chinese Biopharmaceutical Companies in R&D Strength (2023)"
Selected for inclusion in the S&P Global Sustainability Yearbook (China Edition) 2023
Named "Forbes China Best Innovative Practice Employer of the Year 2023"
Gan & Lee Pharmaceuticals obtained Customs AEO (Authorized Economic Operator) Certification
Honored as "Overseas Expansion Enterprise of the Year with the Most Investment Value"
Dr. Zhongru Gan, named to the "2023 Forbes China · Top 100 Most Influential Chinese Elite" list
Dr. Fuming Xu, Executive Director of R&D, named to the "2023 Forbes China · Top 100 Young Overseas Returnee Elite" list
Achieved AAAAA (Five A) Grade in the High-Tech Enterprise Innovation Capability Evaluation
Awarded the Pharmaceutical & Biotech Industry Track Champion Award (2023)
Awarded the 7th Beijing Invention Patent Award (2023)
Ranked 24th on the "2022 Top 100 Beijing Private Enterprises in Technological Innovation" list
Ranked 19th on the "2022 Top 100 Beijing Private Enterprises in Social Responsibility" list
Ranked 51st on the "Beijing Top 100 Manufacturing Enterprises" list
2021 Outstanding Industrial Contribution Award for China Listed Companies
Named "Innovative Pharmaceutical Company of the Year" at the 2021 Ivy Awards
Recognized as a "Beijing Enterprise Innovation Credit Trailblazer Enterprise (2021)"
Rapilin® and Rapilin®30 Awarded the honorary recognition of Beijing New Technology and New Products
AAA grade credit enterprise in pharmaceutical industry in 2021
Basalin® wins 2021-2022 Best Selling Brand of the Year in the Pharmaceutical Retail Market
Dr. Zhongru Gan named one of the "Top 10 Figures in the Pharmaceutical Industry" at the 14th Healthy China Forum
Top 20 biopharmaceutical (including blood, vaccine, insulin, etc.) companies in China in 2021
Dr. Wei Chen was listed on “the 36 2022 Krypton Global Chinese Elite power 100 list”
Gan & Lee Pharmaceuticals wins again China Pharmaceutical Industry Top 100 Honors
Top 100 Beijing Private Enterprises in” Science and Technology” “Innovation and Social Responsibility “for 2022
Kai Du was listed in the “2022 outstanding returnees“ 100 list
Pharmaceutical and Biological Industry Track Winners Award
Certified as a "National Green Supply Chain Enterprise"
Designated as a "National Intellectual Property Demonstration Enterprise"
Honored as a "Growth Outstanding Enterprise" at the 13th Five-Year Plan Enterprise Management Awards
Insulin Aspart Injection recognized as "Breakthrough Drug of the Year"
Ranked on the "2021 China Listed Companies Brand Value New Force Top 50"
Awarded "2021 Forbes China • Most Innovative HR Management Employer of the Year"
Honored as "Industry Pioneer among China Carbon Companies"
Ranked on the "2020-2021 TOP 100 Pharmaceutical Industry Comprehensive Competitiveness Index List"
Awarded "2021 Ivy Award - Innovative Pharmaceutical Company of the Year"
Honored as "China New Economy's Most Investable Listed Company"
GLR2007 (CDK4/6 Inhibitor), the company's self-developed novel drug, selected as "Annual Top 10 Promising Heavyweight Anti-Cancer Innovative Drug Cases"
Awarded "Outstanding Enterprise Brand in API Export"
Ranked on the 2020 China Top 100 Pharmaceutical Enterprises List
Ranked 53rd on the "2020 Top 100 Beijing Private Enterprises in Social Responsibility" list
Ranked 39th on the "2020 Top 100 Beijing Private Enterprises in Technological Innovation" list
Awarded the "2021 Outstanding Industrial Contribution Award for China's Listed Companies"
Awarded "Outstanding Product Brand in Endocrine & Hormone Category" within the Chinese Chemical Pharmaceutical Industry (2021)
Awarded "Outstanding Enterprise Brand in API Export" within the Chinese Chemical Pharmaceutical Industry (2021)
Awarded "Outstanding Product Brand in Biochemical & Biological Products" within the Chinese Chemical Pharmaceutical Industry (2021)
Awarded the Second Prize of the Beijing Science and Technology Progress Award
Designated as a "Key High-Precision and Advanced Enterprise" in Tongzhou District
Ranked on the 2019 China Top 100 Pharmaceutical Enterprises List
Ranked among the Top 100 Beijing Private Enterprises in Technological Innovation (2019)
Honored as "Top 10 in Pharmaceutical & Biotech Industry Value Investment - Golden Intelligence Awards"
Certified as "Best Innovative Growth Enterprise" in the 2020 Annual BioTech Industry Rankings
Ranked among the Top 100 Chinese Chemical Pharmaceutical Enterprises by Comprehensive Strength (2020)
Awarded "Most Socially Responsible Listed Company" at the 10th China Securities Golden Bauhinia Awards
Recognized as a "2020 Corporate Social Responsibility Contribution Enterprise"
Awarded "Outstanding Product Brand in Biochemical & Biological Products" within the Chinese Chemical Pharmaceutical Industry (2020)
Designated as a Beijing Design Center for High-precision and Advanced Industries
Recognized as a Beijing Municipal Enterprise Technology Center
Won the 2019 China Chemical and Pharmaceutial Industry Environmental Protection, Green Pharmaceutial Special Award
Recombinant insulin glargine injection won the 1st prize of science and techonology of Chinese Pharmaceitical Association
Won the National High-tech Enterprise Certificate
Recognized as an "Industry Leader Enterprise" under the Beijing Biomedical Industry Leapfrog Development Project (G20 Project) (2016-2020)
Designated as a "Beijing Municipal Patent Demonstration Unit"
Glargine (Basalin®) Received significant support as one of the national"Three Key Projects"
Approved to establish a Postdoctoral Research Workstation
Awarded the First Prize of the Tongzhou District Science and Technology Award
"Molecular Chapterone Technology" won China Invention Patent Gold Award
Glargine insulin (Basalin®)became a biomedicine major category supported by the national major scientific and technological special project for "Significant New Drugs Development" during the "12th Five-Year Plan" period
Named a "Forbes China Most Promising Non-listed Company"
Awarded the Third Prize of the Beijing Science and Technology Progress Award
Basalin®(insulin glargine injection) became a major biopharmaceutical supported by the National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the 11th Five-Year Plan period
Selected as one of the "Top 100 Most Investable Enterprises in China's Healthcare Industry 2011".
Honored as a "Scale Enterprise" under the Beijing Biomedical Industry Leapfrog Development Project (G20 Project).
Ranked among the "Deloitte Technology Fast 50 China 2011".
Obtained the Certificate of Beijing High and New Techonology Achievement Conversion Project
Recognized as a "Capital Greening and Beautification Garden-style Unit"
Awarded the Second Prize of the National Science and Technology Progress Award
For more information, please visit our CN website.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.